Coronavirus vaccine - Infectious Disease Research Institute
Alternative Names: COVID-2019 vaccine - Infectious Disease Research Institute; RNA COVID vaccine - Infectious Disease Research Institute; RNA COVID-19 vaccine - Infectious Disease Research Institute; SARS-CoV-2 vaccine - Infectious Disease Research InstituteLatest Information Update: 08 Dec 2021
At a glance
- Originator Infectious Disease Research Institute
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 19 Nov 2021 ImmunityBio plans to submit clinical trial application to South African Health Products Regulatory Authority (SAHPRA) for initiation of phase I/II trial in COVID-2019 infections
- 19 Nov 2021 ImmunityBio plans a phase I/II trial in COVID-2019 infections (prevention) in South Africa
- 08 Nov 2021 Amyris enters a joint venture agreement with ImmunityBio for Coronavirus vaccine